greater in women than in men, and did not differ by treatment modality. Electrodesiccation and cryotherapy were more effective than podophyllin for the treatment of external genital warts, but none of these three treatments were highly successful.
Treatment of genital warts is often frustrating for clinicians and patients alike.' Unlike single-dose therapy for many bacterial sexually transmitted diseases (STD), genital warts may require multiple applications of a local destructive therapy. Such therapy is often painful and sometimes unsuccessful. Moreover, genital warts commonly recur after "successful" therapy. Podophyllin has been the most common method of therapy for genital warts in public STD clinics because of its convenience and low cost, but low clearance rates *Non-comp-iant patients.
Stone, Becker, Hadgu, Kraus females. In men, the clearance rate for gay/bisexual men was lower than, but not significantly different from, the clearance rate in heterosexual men (9/27 vs 39/91;p = 04).
Discussion
This study confirms previous observations that cryotherapy and electrocautery produce higher clearance rates than podophyllin for external genital warts, and that none of these methods are highly successful. Some previous studies reported that response to genital wart therapy is influenced by individual wart area,67 total wart area,78 duration,68 and anatomic site.9 In our study, individual wart size was not addressed, and total cubic volume did not affect clearance rates in any of the treatment groups. Only in patients treated with podophyllin did the duration ofwarts appear to affect clearance rates, and differences were not large. However, our sample size is too small to detect a significant difference. Newer warts may be more amenable to treatment than older warts because they are less heavily keratinised. Keratinisation would be expected to impede local therapy with podophyllin, but not with more destructive methods such as cryotherapy or electrodesiccation. Anal warts were no more resistant to therapy than genital warts in our study; however, because only seven evaluable patients had anal warts, the statistical power to detect a significant difference is low. Although some studies have found that anal warts are more difficult to treat than genital warts,9 such differences may be related to host factors rather than to differences in anal epithelium. In women, anal warts are no more resistant to treatment than genital warts.9 In contrast, anal warts in gay men may be a marker for immunosuppression,`0 and a recent study found that HIV-induced immunosuppression was clearly related to lower clearance rates for anogenital warts."
The higher clearance rate in females may relate to higher rates of spontaneous regression7 or greater ease of eradication of warts in nonkeratinised areas, compared to keratinised sites. Earlier presentation to the clinic, when warts were smaller and fewer in number, does not explain this difference, since wart volume and duration were similar for males and females.
This study clearly illustrates the poor compliance with therapy which is common among public STD clinic populations. Low compliance provides a potential source ofbias in our study results; however, failure to complete the therapy regimen and losses to follow up were high in all treatment groups. Monetary incentives might have improved compliance, but would have limited the generalisability of our findings. Factors which may affect treatment outcome and recurrence but were not assessed in our study include concurrent HIV infection, presence of warts in the anal canal, adjacent subclinical human papillomavirus infection, and exposure to partners with warts. Misdiagnosis of other epithelial conditions (pearly penile papules, molluscum contagiosum, fibroepithelial polyps, heterotopic sebaceous glands) as genital warts is a potential source of misclassification. However, the randomised design of this study should have minimised the likelihood of bias due to any of these factors.
Public STD program managers and clinic staff, as well as private physicians, should evaluate the feasibility of offering cryotherapy or electrodesiccation to treat genital warts. A comparison of costs and benefits of cryotherapy or electrocautery might show them to be less expensive than podophyllin, since fewer clinic visits are required. Other than a liquid nitrogen storage tank which must be refilled periodically, the equipment required for cryotherapy is fairly simple: an insulated dispensing container (such as a ThermosTM) and cotton-tipped wooden sticks. Electrodesiccation is more complicated and time-consuming, since it requires a special apparatus, injection of local anaesthesia, and careful positioning of the patient on a ground pad. Initial outlay for electrodesiccation equipment is greater than for cryotherapy; however, recurring costs are minimal. Cryotherapy and electrocautery both are considered surgical procedures, and should be performed only by personnel who are adequately trained and supervised. In some jurisdictions, malpractice policies may not allow such procedures to be performed by nurses. Many clinicians and patients welcome alternative therapies to podophyllin for genital warts.
Podophyllotoxin (recently renamed podofilox), one of the active ingredients in crude podophyllin resin, is being evaluated in the U.S. and elsewhere as an alternative to podophyllin. Efficacy appears similar to that of podophyllin. However, podophyllotoxin offers many advantages over the crude resin: less local toxicity, purity, stable shelflife, and negligible systemic absorption. " Recently, interferon was licensed for intralesional therapy of external genital warts." However, success 
